Selecting patients with ‘sufficient life expectancy’ for Phase I oncology trials remains challenging. The Royal Marsden Hospital Score (RMS) previously identified high-risk patients as those with ⩾2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback